TITLE

FDA Raises Heart Alert on Widely Used Antibiotic

PUB. DATE
March 2013
SOURCE
MondayMorning;3/18/2013, Vol. 21 Issue 10, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses the warning by the U.S. Food and Drug Administration on the health risks related to antibiotic Azithromycin. It is mentioned that heart's electrical activity is changed due to antibiotic which can lead to irregular heart rhythm that could be fatal in some patients. Also mentioned is that aging patients or patients with heart problem history have high risk chances.
ACCESSION #
86435096

 

Related Articles

  • New study finds increased risk.  // OB/GYN Clinical Alert;Jul2012, Vol. 29 Issue 3, p1 

    The article focuses on a new research which reveals that the use of azithromycin, the macrolide causes increased risks for cardiac diseases despite of earlier research depicting just the opposite. According to the research in Tennessee, patients given with azithromycin suffered increased risk of...

  • FDA actions. Elliott, William T. // Neurology Alert;May2013, Vol. 31 Issue 9, Special section p2 

    The article reports that the U.S. Food and Drug Administration (FDA) warns against the use of azithromycin due to its association with fatal heart rhythms and of calcitonin salmon due to its association with a small increased risk of cancer.

  • Azithromycin -- The Heart of the Matter Redux: Preexisting Risks Tell the Tale. Deresinski, Stan // Internal Medicine Alert;9/29/2013, Vol. 35 Issue 18, p141 

    The article comments on a study led by H. Svanström related to the risk of cardiovascular deaths in association with the antibiotic azithromycin use and mentions that azithromycin may increase risk of cardiovascular death in individuals with pre-existing risk factors such as cardiac disease.

  • FDA actions. Elliott, William T. // Neurology Alert;May2013 Pharmacology Watch, p2 

    The article reports on a warning issued by the U.S. Food and Drug Administration (FDA) regarding azithromycin and cardiac toxicity, and the use of calcitonin salmon for the treatment of osteoporosis in postmenopausal women.

  • Upcoming for ADHD meds: Black box warning?  // Contemporary Pediatrics;Mar2006, Vol. 23 Issue 3, p16 

    Reports on the outcome of a meeting held by the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration in February 2006. The activity was centered on discussing a possible connection between stimulant drugs used to treat attention deficit hyperactivity...

  • FDA approves another triptan for migraine in adults.  // Drug Topics;2/4/2002, Vol. 146 Issue 3, p22 

    Reports that the U.S. Food and Drug Administration approved the release of the triptan drug called frovatriptan, from the Ireland-based Elan Corp., for the treatment of migraine in adults. Contraindication of frovatriptan in patients with ischemic heart disease; Pharmacokinetic factors of...

  • US to keep rosiglitazone on market.  // Pulse;8/2/2007, Vol. 67 Issue 29, p2 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to keep rosiglitazone on the market, despite new research adding to concerns over its adverse effect on the heart. An advisory panel convened by the FDA voted 22 to one to allow continued marketing of the drug,...

  • FDA: Potentially harmful stimulant found in Slimming Beauty capsules 'All natural' products contain controlled substance sibutramine.  // Biomedical Market Newsletter;12/20/2010, p62 

    The article reports that the U.S. Food & Drug Administration (FDA) today advised consumers who have Slimming Beauty Bitter Orange Slimming Capsules not to use the product. FDA said that Slimming Beauty Bitter Orange Slimming Capsules contain the active pharmaceutical ingredient sibutramine, a...

  • FDA to Reassess Safety-Risk Evidence for Glaxo's Avandia.  // MondayMorning;4/15/2013, Vol. 21 Issue 14, p1 

    The article offers information on second regulatory review of the diabetes pill Avandia by the pharmaceutical company GlaxoSmithKline PLC due to heart risks caused by this drug. It mentions that this pill was restricted in European and U.S. market due to these heart risks. It further states that...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics